Anavex Life Sciences Corp. AVXL 深 滬
已收盤 07-02 16:00:00 美东时间
2.76
+0.180
+6.98%
華盛通- 最 高2.785
- 今 開2.60
- 成交量 117.50万股
- 最 低 2.57
- 昨 收 2.58
- 總市值 2.56亿
- 52周最高 13.99
- 市盈率 靜 --
- 換手率 1.27%
- 52周最低 2.41
- 委 比 -7.32%
- 總股本 9267.18万
- 歷史最高 31.50
- 量 比 0.74
- 振 幅 8.33%
- 歷史最低 0.60
- 每 手 1
- 風險率 3.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anavex Life Sciences sets 2026 annual shareholder meeting
Anavex Life Sciences sets 2026 annual shareholder meeting Anavex Life Sciences will hold its 2026 annual meeting of stockholders on Sept. 24, 2026 in New York. The board set July 31, 2026 as the record date to determine stockholders entitled to notice and to vote. Disclaimer: This news brief was cre
06-26 18:19
Anavex receives Nasdaq delinquency notice over late quarterly filing
Anavex receives Nasdaq delinquency notice over late quarterly filing Anavex received a Nasdaq delinquency notice on May 20, 2026, citing noncompliance with Listing Rule 5250(c)(1) tied to its failure to file its Form 10-Q for the quarter ended March 31, 2026, on time. The company has until July 20,
05-22 20:16
Anavex Life Sciences Receives Expected Delinquency Notification From Nasdaq
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it
05-22 20:03
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Anavex Life Sciences Corp. (AVXL) received a delinquency notice from Nasdaq on May 20, 2026, for failing to file its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). The notice does not immediately affect the company's stock listing. Anavex is working to complete the filing and regain compliance.
05-22 12:00
Anavex Life Sciences Announces COO Departure Amid Restructuring
Anavex Life Sciences ( ($AVXL) ) has provided an announcement. On May 11, 2026,...
05-16 06:01
Anavex Delays Quarterly Filing Amid CEO Shake-Up
Anavex Life Sciences ( ($AVXL) ) has released a notification of late filing. An...
05-12 07:19
Anavex slips after CEO transition
Shares of Anavex Life Sciences (AVXL) fell ~3% on Wednesday after the Alzheimer’s drug developer named its former R&D head, Terrie Kellmeyer, as its interim chief executive following the departure of ...
05-06 22:29
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
Anavex Life Sciences Corp. announced that Terrie Kellmeyer, PhD, has been appointed as Interim Chief Executive Officer following the departure of Christopher Missling, PhD, MS, MBA. Dr. Kellmeyer, a seasoned pharmaceutical executive with nearly three decades of experience, will lead the company's next phase of growth, focusing on advancing its clinical development programs, including its lead candidate, oral blarcamesine, for early Alzheimer’s di...
05-06 11:00
Anavex Life Sciences Announces New Findings On The Shared Biology Between Autism Spectrum Disorder And Alzheimer's Disease
Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD) and Alzheimer's disease (AD), including shared disruptions in autophagy.Epidemiological data show that autistic adults
04-14 19:34
Anavex Life Sciences to present at Needham Virtual Healthcare Conference
Anavex Life Sciences to present at Needham Virtual Healthcare Conference Anavex Life Sciences will present at Needham 25th Annual Virtual Healthcare Conference, scheduled for April 14, 2026 at 1:30 p.m. ET. Conference runs April 13-16, 2026. Disclaimer: This news brief was created by Public Technolo
04-07 19:32
